Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico

Vela‐Ojeda, Jorge; Gómez‐Almaguer, David; Espinoza-Zamora, Ramiro; Ramírez-Alvarado, Aline G.; Villalobos, Alberto; Herrera-Rojas, Miguel Ángel; Alvarado-Ibarra, Martha; Pérez-Ramírez, Oscar de Jesús; Sandoval-Villa, Celia Carela; Loarca-Piña, Luis Martín; Ceballos-López, Adrián Alejandro; Rivas-Lamas, José Ramón; García-Castillo, Carolina; Ruíz‐Argüelles, Guillermo J.

doi:10.1016/j.arcmed.2021.02.008

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Přínos daratumumabu pro nemocné s extramedulárním šířením myelomových buněk je podstatně menší než u pacientů bez extramedulárního šíření(110,111).Podobné výsledky má i analýza Slovenské myelomové skupiny(112). Menší efektivitu léčby daratumumabem při extramedulárních ložiscích ve srovnání s pacienty bez těchto extramedulárních ložisek zaznamenali i další autoři(113,114).Mnohočetný myelom může vytvářet i leptomeningeální poškození. Daratumumab má potenciál dosáhnout dostatečnou koncentraci v cerebrospinálním moku a lze jej použít i pro léčbu této formy nemoci obvykle ve spojení s radioterapií(115,116).7 Léčba chorob ze Monoclonal Gammopathy of Clinical Significance daratumumabemKlinická jednotka Monoclonal Gammopathy of Clinical Significance byla popsána auto ry Mayo Clinic v roce 2018.…”

unclassified

Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients

Adam¹,

Pour²,

Krejčí³

et al. 2022

Onkologie

View full text Add to dashboard Cite

Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patientsMultiple myeloma (MM) is a hematological malignancy characterized by renal insufficiency, bone lesions, anaemia, and hypercalcemia. In this modern era of medicine, even with the development of drugs like immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI), the treatment of MM prevails as a challenge. However, even after the attainment of total remission, relapse of MM and disease progression is frequent. That is why there is an urgent requirement to develop novel monoclonal antibody drugs. The latest drugs for the treatment of relapsed and refractory MM (RRMM) approved by the Food and Drug Administration (FDA) is daratumumab. In this article, we will discuss daratumumab with different combination therapies in multiple myeloma, but also in other indications. Information about the efficacy in various type of Monoclonal Gammopathy of Clinical Significance are reviewed. Several studies tested daratumumab in autoimmune diseases with positive results. The goal of this publication is to give information about all indication in which daratumumab was tested with positive results. And we alsou inform about our own experiencies with daratumumab, lenalidomide dexamethasone in 74 pacients treated in the year 2018-2021.

show abstract